

RESEARCH ARTICLE

Open Access

Phenotypic and genotypic properties of *Microbacterium yannicii*, a recently described multidrug resistant bacterium isolated from a lung transplanted patient with cystic fibrosis in France

Poonam Sharma¹, Seydina M Diene¹, Sandrine Thibeaut¹, Fadi Bittar¹, Véronique Roux¹, Carine Gomez², Martine Reynaud-Gaubert^{1,2} and Jean-Marc Rolain^{1*}

Abstract

Background: Cystic fibrosis (CF) lung microbiota consists of diverse species which are pathogens or opportunists or have unknown pathogenicity. Here we report the full characterization of a recently described multidrug resistant bacterium, *Microbacterium yannicii*, isolated from a CF patient who previously underwent lung transplantation.

Results: Our strain PS01 (CSUR-P191) is an aerobic, rod shaped, non-motile, yellow pigmented, gram positive, oxidase negative and catalase positive bacterial isolate. Full length 16S rRNA gene sequence showed 98.8% similarity with *Microbacterium yannicii* G72T type strain, which was previously isolated from *Arabidopsis thaliana*. The genome size is 3.95Mb, with an average G+C content of 69.5%. *In silico* DNA-DNA hybridization analysis between our *Microbacterium yannicii* PS01 isolate in comparison with *Microbacterium testaceum* StLB037 and *Microbacterium laevaniformans* OR221 genomes revealed very weak relationship with only 28% and 25% genome coverage, respectively. Our strain, as compared to the type strain, was resistant to erythromycin because of the presence of a new *erm* 43 gene encoding a 23S rRNA N-6-methyltransferase in its genome which was not detected in the reference strain. Interestingly, our patient received azithromycin 250 mg daily for bronchiolitis obliterans syndrome for more than one year before the isolation of this bacterium.

Conclusions: Although significance of isolating this bacterium remains uncertain in terms of clinical evolution, this bacterium could be considered as an opportunistic human pathogen as previously reported for other species in this genus, especially in immunocompromised patients.

Keywords: Cystic fibrosis, Antibiotic resistance, Multidrug resistant bacteria, *Microbacterium yannicii*

Background

Cystic fibrosis (CF) is one of the most common inherited autosomal recessive disease in the Caucasian population. It is due to mutations in the product of the gene encoding the CF transmembrane conductance regulator (CFTR), resulting in chloride channel dysfunction conductance

regulator gene [1]. Although CF is a multisystemic disease, the clinical picture is generally dominated by pulmonary involvement, the main cause of morbidity and mortality in this disease. Lung disease is characterized by recurrent and alternative cycles of airway infection and inflammation, leading to bronchiectasis and subsequently to respiratory failure where lung transplantation may constitute the ultimate therapeutic option [2]. Infections in CF patients are considered to be polymicrobial [3]. The pathogens which are traditionally involved include *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus*

* Correspondence: jean-marc.rolain@univ-amu.fr

¹Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), CNRS-IRD, UMR 6236, Méditerranée Infection, Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27 Bd Jean Moulin, Marseille Cedex 05 13385, France

Full list of author information is available at the end of the article

influenzae and *Burkholderia cepacia* complex [4-7]. Many studies have shown that the community of microbes present in the airway of CF patients is more diverse and complex than previously thought [3,8-10]. Many new, emerging and/or multidrug resistant bacteria have been recently reported in CF patients using different technologies including new culture media and molecular methods [3,8,11,12]. In this study, we report the isolation and full description of *Microbacterium yannicii* isolated from the sputum sample from a lung transplanted CF adult patient for which we have recently published the genome sequence [13]. *Microbacterium yannicii* G72T the reference type strain isolated from surface sterilized roots of *Arabidopsis thaliana* was used for comparison [14]. The genus *Microbacterium* was first proposed in 1919 [15]. *Microbacterium* sp. belongs to the family Microbacteriaceae [16,17], order Actinomycetales, class Actinobacteria [17] which comprises mainly aerobic Gram positive bacteria with high G+C content and a peptidoglycan defined by a B-type cross linkage [18]. Based on phylogenetic properties and chemotaxonomic features, the genera *Microbacterium* and *Aureobacterium* were unified to form the redefined genus *Microbacterium* in 1998 [19]. From mid 1990s, the presence of *Microbacterium* was recognized in human clinical specimens [20-22]. However, to the best of our knowledge, bacteria of this genus have never been reported in clinical samples from CF patients. Here, we present a full description of phenotypic and genomic properties of this new bacterium isolated from a CF sputum sample.

Case report

A 23-year-old woman who has been lung transplanted for CF (heterozygote delta F508/1717-1G genotype) was admitted in emergency in November 2010 in our medical department for acute respiratory failure in the context of uncontrolled CF-related diabetes with ketoacidosis coma. She required rapidly mechanical ventilation support, adapted metabolic adjustment, diabetes management, and nutritional supporting care. Her medical history included long term colonization by multi drug resistant *Pseudomonas aeruginosa* and *Burkholderia multivorans*. She had undergone bilateral lung transplantation when she was 19 years old, and 2 years later, she developed progressive chronic lung allograft dysfunction (CLAD) with a bronchiolitis obliterans syndrome (BOS) stage 3 since the last 6 months and a respiratory insufficiency requiring oxygen supplement 2 months before the admission. The immunosuppressive regimen on admission consisted of tacrolimus (trough level around 8 to 10 ng/ml), mycophenolate mofetil (500 mg twice daily) and azithromycin 250 mg daily for BOS for more than one year. The worsening of respiratory function was associated with the persistence of

Pseudomonas aeruginosa and *Burkholderia multivorans* colonization along with appearance of *Aspergillus fumigatus*. During hospitalization in the ICU, probabilistic antibiotherapy consisted of an association of ceftazidime, tobramycin and inhaled colistin. After an initial improvement, despite she still required oxygenotherapy device and intermittent noninvasive ventilation support, her respiratory function worsened on January 2011. A sputum sample was collected on January 7th, in which multiresistant *Pseudomonas aeruginosa* and *Burkholderia multivorans* were isolated on chocolate Poly ViteX agar (bioMérieux, Marcy l'Etoile, France) and cepacia agar (AES laboratory, Combourg, France), respectively. An atypical gram positive strain was isolated at 10^5 CFU/ml on Columbia CNA agar plate. A treatment with ceftazidime, temocillin and inhaled colistin was started again. Her respiratory function continued to deteriorate and she died after 2 months in a septic clinical condition.

Results

Phenotypic features

The gram positive strain was isolated on Columbia colistin-nalidixic acid CNA agar with 5% sheep blood (bioMérieux), after 24 hours of incubation at 37°C with 5% CO₂ (Figure 1A,1B,1C). It also grew on COS medium at 29°C after 24 hours. The colonies are 0.1-0.2 mm in diameter. The isolate was an aerobic, yellow pigmented (Figure 1A), rod-shaped, non-motile, oxidase negative and catalase positive bacterium. This strain was able to grow in microaerophilic atmosphere but not in anaerobic atmosphere. It also grew very weakly at a salt concentration of up to 10% after 48 hours of incubation. As the spectrum for *Microbacterium yannicii* was not available in the Bruker database at the time of our strain isolation, we were not able to identify correctly and after the addition of *Microbacterium yannicii* G72 type strain spectrum in our local database, our strain was identified as *Microbacterium yannicii* with a low score (Score 1.3). Hence, we proceeded with 16SrRNA sequencing for precise identification. Table 1 outlines the results of the commercial phenotypic tests done which includes apiCoryne, apiCH-50 and apiZYM (BioMérieux, Marcy l'Étoile, France) tests to distinguish the CF clinical isolate from five type strains of the genus *Microbacterium* including *Microbacterium yannicii* G72T DSM 23203, *Microbacterium trichothecenolyticum* DSM 8608, *Microbacterium flavescens* DSM 20643 and *Microbacterium hominis* DSM 12509. In apiZYM, the enzymatic reaction for β-glucuronidase was positive for CF *Microbacterium yannicii* PS01 as well as *Microbacterium yannicii* G72T (DSM 23203). Although some of the biochemical tests for our strain yielded results similar to those reported for *M. yannicii* G72 type strain [14], however, we found at least nine differences between our isolate and the type




Figure 1 Colonial morphology, gram staining and transmission electron microscopic image of the CF clinical isolate *Microbacterium yannicii* PS01. **A.** CF clinical isolate *Microbacterium yannicii* PS01 was grown on Columbia colistin-nalidixic acid agar with 5% sheep blood (bioMérieux) at 37°C with 5% CO₂. The colony appeared as yellow, round and smooth. **B.** Gram staining picture of the gram-positive coccobacilli CF clinical isolate "CF *Microbacterium yannicii* PS01" viewed at 100X magnification. **C.** Transmission electron microscopy image of *M. yannicii* strain PS01, using a Morgani 268D (Philips) at an operating voltage of 60kV. The scale bar represents 900 nm.

strain that are presented in Table 1 along with comparison to the three other type strains. Antibiotic susceptibility was determined on Columbia agar with 5% sheep blood (COS) (bioMérieux) as per CA-SFM guidelines for *Coryneform* species. Table 2 shows the antibiotic susceptibility pattern of these five strains. The CF clinical strain was resistant to fosfomycin, erythromycin, clindamycin, gentamicin, tobramycin, ciprofloxacin and ofloxacin. The CF clinical isolate was also resistant to trimethoprim-sulfamethoxazole whereas *M. yannicii* G72 type strain was not (Table 2).

Genotypic features

The 16S rRNA sequence of our isolate Strain PS01 showed 98.8% similarity with *Microbacterium yannicii* G72T strain (DSM23203) (GenBank accession number FN547412), 98.7% with *Microbacterium trichothecenolyticum*, and 98.3% similarity with both *Microbacterium flavescens* and *Microbacterium hominis*. Based on 16S rRNA full length gene sequence (1510 bp), our isolate was identified as *Microbacterium yannicii*. Partial *rpoB* sequences (980 bp) as well as partial *gyrB* sequences were also determined for the four strains and a

concatenated phylogenetic tree was constructed to show the phylogenetic position of CF *Microbacterium yannicii* PS01 (Figure 2).

Genome analysis and comparison

The genome of CF *Microbacterium yannicii* (Strain PS01, CSUR Reference No.P191) was sequenced and the draft genome sequence has been deposited in EMBL under the accession number CAJF01000001-CAJF01000067 [13]. The genome exhibits a total size of 3,952,501 bp and a G+C content of 69.5% (Table 3). We performed *in silico* DNA - DNA hybridization of the whole genome of CF *Microbacterium yannicii* against the two available genomes in this genus i.e. *Microbacterium testaceum* StLB037 and *Microbacterium laevaniformans* OR221 and the overall results are presented in Table 3. At E-value 1.00e-5, the species coverage in *Microbacterium testaceum* StLB037 and *Microbacterium laevaniformans* OR221 was only 28% and 25.05%, respectively (Table 3). The numbers of proteins with no similarity in comparison to CF *Microbacterium yannicii* were 882 and 988 and with similarity up to 80% were 598 and 580 of *Microbacterium testaceum* StLB037 and *Microbacterium laevaniformans*

Table 1 Comparison of phenotypic characteristics of *M. yannicii* PS01 with closely related species

Characteristics	<i>CFM.yannicii</i>	<i>M.yannicii</i>	<i>M.trichothecenolyticum</i>	<i>M.flavescens</i>	<i>M.hominis</i>
Colour of the colony	Yellow	Yellow	Yellow	Yellow White	Yellow White
Motility	No	No	No	No	No
Growth at 29°C	Yes	Yes	Yes	Yes	Yes
Growth at 37°C	Yes	Yes	Yes	Yes	Yes
CAT	+	+	+	+	+
OXI	-	-	-	-	-
apiZYM					
Esterase lipase	+	+	W+	W+	+
Cystine arylamidase	W+	+	W+	W+	W+
α-chymotrypsin	-	-	+	+	-
Naphthol-AS-BI-phosphohydrolase	-	+	+	-	-
β-glucuronidase	+	+	-	-	-
α-fucosidase	-	+	W+	-	-
Assimilation of apiCH50					
DARA	-	+	-	+	-
RIB	-	+	-	-	-
DXYL	-	+	+	+	+
GAL	-	+	+	-	+
RHA	-	-	-	+	+
NAG	-	-	W+	-	+
MEL	-	+	-	-	-
TRE	+	+	-	+	+
INU	+	-	-	-	-
AMD	-	+	W+	-	+
GLYG	-	+	-	-	+
GEN	-	+	-	-	+
DFUC	+	+	-	-	-
Api CORYNE					
Pyr A	-	-	+	+	-
β GUR	+	+	-	-	-
GEL	+	+	-	+	-

Phenotypic characteristics Specific phenotypic characteristics of the CF isolate and comparison with closely related *Microbacterium* spp. Strain 1: *M. yannicii* DSM 23203, Strain 2: CF *M. yannicii* PS01, Strain 3: DSM 8608 *M. trichothecenolyticum*, Strain 4: DSM 20643 *M. flavescens* and Strain 5: DSM 12509 *M. hominis*. Abbreviation List: + Positive; - Negative; W+ weakly positive; CAT-Catalase; OXI-Oxidase; DARA-D-Arabinose; RIB-Ribose; DXYL-D-Xylose; RHA-L-Rhamnose; NAG-N-AcetylGlucosamine; MEL-D-Melibiose; TRE-D-Trehalose; INU-Inulin; AMD-Amidon; GLYG-Glycogen; GEN-Gentiobiose; DFUC-D-Fucose; PYRA-Pyroglytamic acid-β-naphthylamide; GUR-Naphthol ASBI-glucuronic acid; GEL-Gelatin (Strictly anaerobic); O-Negative control.

OR221, respectively (Table 3). We analyzed the resistome of CF *M. yannicii* PS01 and found that there were 11 ORFs corresponding to Beta-lactamase family proteins, 5 ORFs corresponding to Aminoglycoside phosphotransferase family proteins that could explain the resistance of this isolate to aminoglycosides, 1 ORF corresponding to a macrolide efflux protein family and a new *erm* gene encoding a 23S rRNA N-6-methyltransferase that could explain the resistance to erythromycin (Table 2 and Table 4). *Microbacterium yannicii* G72T reference strain was susceptible to erythromycin and after designing

primers targeting the new *erm* gene we found that this reference strain do not contain this gene as PCR was only positive for our CF isolate (data not shown). We also found mutations in *gyrA* (Ser83Ala) and *parC* (Ser80Ala) that were likely the cause of resistance against fluoroquinolone compounds (Table 2 and Table 4). Resistance to trimethoprim-sulfamethoxazole was likely due to the presence of a DHPS encoding gene (Table 4). We also found 17 ORFs for multidrug efflux transporters such as ion channels, multidrug ABC transporters, amino acid transporters, and major facilitator superfamily proteins

Table 2 Antibiotic susceptibility testing of *M. yannicii* PS01 with closely related species

Antibiotic	Abr.	CF <i>M.yannicii</i>	<i>M.yannicii</i>	<i>M.trichothecenolyticum</i>	<i>M.flavescens</i>	<i>M.hominis</i>
Fosfomycin	FOS50	7/R	7/R	7/R	7/R	7/R
Chloramphenicol	C30	S	S	S	16/S	24/S
Doxycycline	D30	S	S	S	7/R	7/R
Erythromycin	E15	7/R	S	S	7/R	34/S
Vancomycin	VA	S	S	S	20/S	14/R
Clindamycin	CM5	8/R	S	12/R	7/R	7/R
Oxacillin	OX5	20/S	S	7/R	7/R	7/R
Rifampicin	RA30	S	S	24/S	28/S	20/S
Colistin	CT50	30/S	20/S	20/S	12/R	10/R
Gentamicin	GM15	12/R	10/R	14/R	7/R	10/R
Tobramycin	TM10	7/R	7/R	7/R	7/R	7/R
Ciprofloxacin	CIP5	7/R	15/R	12/R	7/R	20/S
Ofloxacin	OFX5	7/R	11/R	10/R	7/R	7/R
Trimethoprim-Sulfamethoxazole	SXT	7/R	31/S	24/S	S	S
Amoxicillin	AX25	S	S	S	S	20/S
Imipenem	IMP10	S	S	S	S	S
Ceftazidime	CAZ30	S	7/R	7/R	7/R	16/S
Ticarcilline	TIC75	S	S	7/R	7/R	12/R
Cefoxitin	FOX30	S	20/S	7/R	16/S	26/S
Ceftriaxone	CRO30	S	S	24/S	7/R	S
Amoxicillin-Clavulanic acid	AMC30	S	S	S	S	S

Antibiotic susceptibility testing of CF clinical *M. yannicii* PS01 isolate and *M. yannicii* DSM 23203, *M. flavescens*, *M. trichothecenolyticum* and *M. hominis* reference strains.

S sensitive, R resistant, Numbers given in mm.

which could explain the resistance to other antibiotics (Table 4).

Discussion

Genus *Microbacterium* belongs to the Microbacteriaceae family, which contains species highly related by 16S rRNA gene sequence that are difficult to identify at the species level [19]. In this genus, the only available genomes before our previous work [23] were those of *Microbacterium testaceum* StLB037 and [23] and *Microbacterium laevaniformans* OR221 [24]. We used a polyphasic taxonomic approach for the precise identification of our new species. Firstly, MALDI-TOF-MS was used for the identification of the bacterium. MALDI-TOF-MS, a rapid and reliable method to identify bacterial isolates at the species and subspecies level [25,26] was used for the identification of this bacterium. Although initially, our strain was only identified at the genus level, it was correctly identified as *Microbacterium yannicii* at the species level when spectrum from the reference strain was added to the database (Figure 3). We performed apiZYM, apiCH50, apiCoryne and antibiotic susceptibility phenotypic tests to compare our strain to *Microbacterium yannicii* G72 type strain as well as to

other closely related species (*Microbacterium trichothecenolyticum*, *Microbacterium flavescens* and *Microbacterium hominis*). In these tests, we have found only few differences between our strain and the type strain. For example we found that the reference strain was susceptible to erythromycin whereas our strain was not, and this was likely due to the presence of a 23S rRNA methyltransferase in the genome of our strain that was absent in the reference strain. These differences may be explained by the different lifestyle of the two strains, one living in roots and the other in human respiratory tract leading to different genomic repertoires that can produce alternative or atypical phenotypes that are better adapted to their environment as recently exemplified in *Enterobacter aerogenes* [27]. Finally, whole genome sequence analysis of our strain allows us to fully characterize this new species including the genetic determinants associated with its specific antibiotic resistance phenotype likely acquired from different sources. *In silico* DNA-DNA hybridization of the genome of CF *Microbacterium yannicii* against the two other available genomes (*Microbacterium testaceum* StLB037 and *Microbacterium laevaniformans* OR221) was very low ($\leq 70\%$). This was similar to DNA-DNA hybridization




Table 3 General features of *M.yannicii* PS01 genome in comparison with *M. testaceum* StLB037 and *M. laevaniformans* OR221 genomes

Species	Database accession number	Genome size (bp)	%GC content	No. of CDS	No. of RNA	Alignment length (bp) (cut-off E-value 1.00e-5) ^β	Y ^Δ = 0% Id	Y ^Δ > 80% Id
<i>M. yannicii</i> PS01	CAJF01000001- CAJF01000067 ^α	3,952,501	69.54	3772	56	-	-	-
<i>M. testaceum</i> StLB037	AP012052	3,982,034	70.28	3795	58	1,106,788 (28%)	882	598
<i>M. laevaniformans</i> OR221	AJGR01000001- AJGR01000535 ^α	3,427,400	68.03	3294	72	989,933 (25.05%)	988	580

Table of comparison of *M. yannicii* PS01 genome details in comparison with *M. testaceum* StLB037 and *M. laevaniformans* OR221 genomes.

^α, genome sequences were deposited in Whole Genome Sequence (WGS), 67 contigs for *M. yannicii* and 535 contigs for *M. laevaniformans*;

^β, the "In silico" DNA-DNA hybridization of *M. yannicii* PS01 genome against *M. testaceum* StLB037 and *M. laevaniformans* OR221 genomes, in parenthesis, the percentage of coverage with respect to *M. yannicii* genome; ^Δ, Number of *M. yannicii* proteins with any similarity and with similarity up to 80%.

Table 4 Antibiotic resistance genes in *M.yannicii* PS01 genome

Antibiotic class	Gene name	Size (aa)	Functions	Best blast hit organism in Genbank	% aa identity	E-value
Beta-lactams	<i>ampC</i>	323	Beta-lactamase class C	<i>Isoptricola variabilis</i> 225	56.5	5.00E-114
	<i>ampC</i>	422	Beta-lactamase class C	<i>Microbacterium testaceum</i> StLB037	54	1.00E-123
	<i>ampC</i>	364	Beta-lactamase class C	<i>Paenibacillus mucilaginosus</i> KNP414	37.8	3.00E-59
	<i>ampC</i>	338	Beta-lactamase class C	<i>Arthrobacter aureescens</i> TC1	41.9	4.00E-67
	-	558	Predicted hydrolase of the metallo-beta-lactamase superfamily	<i>Microbacterium laevaniformans</i> OR221	88.8	0
	-	212	Predicted Zn-dependent hydrolases of the beta-lactamase fold	<i>Microbacterium testaceum</i> StLB037	66.9	2.00E-100
	<i>elaC</i>	290	Metal-dependent hydrolases of the beta-lactamase superfamily III	<i>Saccharomonospora paurometabolica</i> YIM 90007	46.6	2.00E-74
	<i>penP</i>	279	Beta-lactamase class A	<i>Microbacterium testaceum</i> StLB037	77.3	7.00E-146
	-	615	Beta-lactamase domain protein	<i>Kribbella flavida</i> DSM 17836	44.2	3.00E-148
	-	626	Beta-lactamase domain protein	<i>Mycobacterium rhodesiae</i> JS60	66.8	0
	-	524	Zn-dependent hydrolase of the beta-lactamase fold	<i>Microbacterium testaceum</i> StLB037	83.8	0.00E+00
Aminoglycoside	<i>aph</i>	51	Aminoglycoside phosphotransferase	<i>Microbacterium laevaniformans</i> OR221	72	2.00E-17
	-	435	Predicted aminoglycoside phosphotransferase	<i>Microbacterium testaceum</i> StLB037	61	3.00E-130
	-	292	Aminoglycoside phosphotransferase	<i>Micromonospora lupini</i> str. Lupac 08	55.9	3.00E-95
	-	308	Aminoglycoside phosphotransferase	<i>Streptosporangium roseum</i> DSM 43021	43.8	7.00E-71
	-	350	Aminoglycoside phosphotransferase	<i>Cellulomonas fimi</i> ATCC 484	60.4	1.00E-125
Macrolides	-	461	Macrolide-efflux protein	<i>Beutenbergia cavernae</i> DSM 12333	65.4	2.00E-166
Fluoroquinolones	<i>gyrA</i> mutated: S83A	883	DNA gyrase subunit A (EC 5.99.1.3)	<i>Microbacterium testaceum</i> StLB037	87.7	0
	<i>parC</i> mutated: S80A	819	Topoisomerase IV subunit A (EC 5.99.1.-)	<i>Microbacterium testaceum</i> StLB037	82.7	0
Sulfamides	<i>dhps</i>	281	Dihydropteroate synthase	<i>Microbacterium laevaniformans</i> OR221	71.6	2.00E-122
Multidrug Efflux pumps	<i>corC</i>	450	Magnesium and cobalt efflux protein	<i>Microbacterium testaceum</i> StLB037	78.4	0
	<i>kefA</i>	373	Potassium efflux system	<i>Microbacterium laevaniformans</i> OR221	74.7	0
	-	548	Putative MFS Superfamily multidrug efflux transporter	<i>Nocardia cyriacigeorgica</i> GUH-2	72.8	0
	-	513	putative efflux MFS permease	<i>Microbacterium laevaniformans</i> OR221	78.8	0
	-	212	Putative threonine efflux protein	<i>Microbacterium testaceum</i> StLB037	61.6	1.00E-80
	-	1275	RND multidrug efflux transporter; Acriflavin resistance protein	<i>Microbacterium laevaniformans</i> OR221	78.1	0
	-	426	antibiotic efflux protein	<i>Microbacterium laevaniformans</i> OR221	83.5	0
	-	526	probable multidrug resistance transporter, MFS family	<i>Cellulomonas fimi</i> ATCC 484	68.8	0

Table 4 Antibiotic resistance genes in *M.yannicii* PS01 genome (Continued)

-	474	Inner membrane component of tripartite multidrug resistance system	<i>Arthrobacter aurescens</i> TC1	68.2	0
-	354	ABC-type multidrug transport system, ATPase component	<i>Saccharopolyspora erythraea</i> NRRL 2338	58.8	1.00E-119
bcr/cfIA	417	Multidrug resistance transporter, Bcr/ CfIA family	<i>Brachybacterium paraconglomeratum</i> LC44	68.5	1.00E-154
-	519	multidrug resistance protein	<i>Arthrobacter aurescens</i> TC1	54.2	8.00E-177
-	332	ABC-type multidrug transport system, ATPase component	<i>Microbacterium laevaniformans</i> OR221	72.2	6.00E-142
-	264	ABC-type multidrug transport system, ATPase component	<i>Microbacterium testaceum</i> StLB037	75	1.00E-143
-	303	ABC-type multidrug transport system, ATPase component	<i>Paenibacillus curdianolyticus</i> YK9	59.5	7.00E-110
-	273	ABC-type multidrug transport system, permease component	<i>Paenibacillus curdianolyticus</i> YK9	67.7	3.00E-121
-	306	ABC-type multidrug transport system, ATPase component	<i>Clavibacter michiganensis</i> subsp. <i>michiganensis</i> NCPPB 382	60.8	3.00E-107

General features of CF *M. yannicii* PS01 resistome showing the antibiotic resistance genes present and percentage of identity with best blast hit organism.




Figure 3 MSP Dendrogram based on different *Microbacterium* species hierarchy along with other species of the genus *Microbacterium* (reference spectra obtained from Bruker database) upon the addition of *Microbacterium yannicii* G72 type strain and CF *Microbacterium yannicii* PS01. (* Spectra generated).

experiments reported in the seminal paper on the description of *Microbacterium yannicii* G72T species by Karojet et al. who showed a genetic relatedness of only 15.9%, 31.2%, and 45.1% between reference strain *Microbacterium yannicii* G72 and *Microbacterium hominis*, *Microbacterium insulae*, and *Microbacterium trichothecenolyticum*, respectively [14]. As all the organ transplant recipients, our patient was immunocompromised, with an over immunosuppressive regimen containing a long macrolide therapy in the context of chronic lung allograft dysfunction, such conditions with might play a crucial role in the development of *Microbacterium* spp. infection or colonization. Indeed *Microbacterium* spp. have been described as a causative agent of infections in immunocompromised patients such as, cancer patients [28,29], endophthalmitis patients [21], interstitial pulmonary infection after heart transplantation [30], bone marrow transplant recipients [31], and bacteremia [32-34]. To the best of our knowledge, such infection with *Microbacterium* spp has not been previously described in the double context of lung transplantation and in cystic fibrosis. *Microbacterium* spp. have been isolated from clinical specimens including blood culture, superficial wounds, pleural fluid, sinus aspirate, bone infection, endophthalmitis, dialysis fluid, lymph node, catheter tip, knee puncture fluid, wound swab, urine, gall bladder, throat swab, prosthetic hip infection, conjunctival swab, tracheal secretion and urethral swab [35]. The source of this bacterium in our patient was also undetermined but in our opinion, plants or vegetables may be a potential source of transmission in CF patients as well as a possible person to person transmission from another patient. Bacteria of the genus *Burkholderia*, *Pandoraea*, or *Pseudomonas* for example, which are known to be frequently recovered in the respiratory tract of CF patients, are also endophytic bacteria in plants. These results reinforce the hypothesis that plant associated environments may act as niche for putative opportunistic human pathogenic bacteria [36].

Conclusions

Our results showed that CF *Microbacterium yannicii*, which has previously been isolated from *Arabidopsis thaliana* roots, has never been reported from a human clinical specimen and its pathogenicity in this context is unknown. Studies have shown that bacteria from this genus have been associated previously with infections, predominantly in immunocompromised patients; however, the isolation of *Microbacterium yannicii* is unclear if it could have been the result of a specific exacerbation observed in this patient. In our study, the patient received immunosuppressive therapy since her lung transplantation. Because the patient was also chronically

colonized by other well-known pathogens, it is difficult to establish the true significance of isolating this bacterium in terms of clinical evolution. Hence, it is hypothesized that this bacterium could be considered as an opportunistic human pathogen in immunocompromised patients but this should be further investigated in the future.

Methods

Bacterial isolate and identification

Microbacterium yannicii G72T reference strain (DSM23203) [14] was used as a control for the comparison of phenotypic and genotypic properties of our strain. Our CF strain was isolated on Columbia CNA agar plate (bioMérieux), and was identified by Matrix assisted Laser desorption and ionization time-of-flight mass spectrometry (MALDI TOF-MS) using a Microflex machine (Bruker Daltonics). The biochemical tests were performed on the commercially available apiCoryne, apiCH-50 and apiZYM test strips (BioMérieux, Marcy l'Étoile, France) according to manufacturer's instructions.

Antibiotic susceptibility test

Antibiotic susceptibility was determined on Columbia agar with 5% sheep blood (COS) (bioMérieux) by disk diffusion method as per CA-SFM guidelines for *coryneform* species and the susceptibility results were interpreted according to the recommendations of the "Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM)" (www.sfm-microbiologie.org/).

PCR and sequencing

To investigate the phylogenetic position of this strain, 16S rRNA, *rpoB* and *gyrB* genes were amplified and sequenced with Big Dye Terminator reagents (Applied Biosystems) ABI 3730 Automated Sequencer and the sequences were blasted against the GenBank database. The sequence of the primers used in this study are 16SrRNA F-5'-AGAGTTTGATCCTGGCTCAG-3', 16SrRNA R-5'-ACGGCTACCTTGTTACGACTT-3', MY *rpoB* F-5'-AAGGGMACSTTCGTCATCAA-3', MY *rpoB* R-5'-CGATCAGACCGATGTTTCGGG-3', MY *gyrB* F-5'-GASSGCSTTCCTSAACAAGG-3' and MY *gyrB* R-5'-GCNCGGAASCCCTCYTCGTG-3'. Sequence alignment was performed using CLUSTAL X, and concatenated phylogenetic tree was constructed using MEGA 5 software (Molecular Evolutionary Genetic Analysis, vers.5, 2011) using neighbor joining tree method and 1000 bootstrap replications [37].

Genome

The genome of this strain was sequenced using Genome Sequencer Titanium (454 Life Sciences, Branford, CT) and reported recently [13]. All contigs from genome

assembly process were submitted to online bioserver "RAST server: Rapid Annotation using Subsystems Technology (<http://www.theseed.org>)" [38] to predict protein-encoding genes, rRNA and tRNA sequences, and assigned functions to these genes. Predicted proteins were compared against Non Redundant (nr) GenBank database using BLASTP (e-value 10^{E-8} ; identity $\geq 30\%$; coverage $\geq 50\%$) and COG databases of the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov>). tRNA and rRNA genes were also verified on tRNAscan-SE Search Server (<http://lowelab.ucsc.edu/tRNAscan-SE>) and RFAM (<http://rfam.sanger.ac.uk>) respectively. Genome comparison was performed by "in silico" DNA-DNA hybridization using BlastN analysis in a local bioserver to determine the full-length alignment between two genome sequences and the coverage percentage using the cut-off stringency of E-value at $1.00e-5$ [30].

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PS carried out all the experiments and wrote the manuscript. SMD carried out the genomics study. ST and CG contributed the case report. VR helped in analyzing data. FB and MRG critically revised the manuscript. JMR conceived the idea, analyzed the data and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Linda Hadjadj for her technical assistance.

Author details

¹Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), CNRS-IRD, UMR 6236, Méditerranée Infection, Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27 Bd Jean Moulin, Marseille Cedex 05 13385, France. ²Centre de Soins de la mucoviscidose et Centre de transplantation Pulmonaire, Centre Hospitalo-Universitaire Nord, chemin des Bourrelly, Marseille 13015, France.

Received: 7 February 2013 Accepted: 30 April 2013

Published: 3 May 2013

References

1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL: **Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.** *Science* 1989, **245**:1066–1073.
2. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, Harris JK: **Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens.** *PLoS One* 2010, **5**:e15101.
3. Bittar F, Rolain JM: **Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients.** *Clin Microbiol Infect* 2010, **16**:809–820.
4. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Loudon L, Ramsey BW, Clausen CR: **Microbiology of sputum from patients at cystic fibrosis centers in the United States.** *Clin Infect Dis* 1998, **27**:158–163.
5. Gibson RL, Burns JL, Ramsey BW: **Pathophysiology and management of pulmonary infections in cystic fibrosis.** *Am J Respir Crit Care Med* 2003, **168**:918–951.
6. Gilligan PH: **Microbiology of airway disease in patients with cystic fibrosis.** *Clin Microbiol Rev* 1991, **4**:35–51.
7. Shreve MR, Butler S, Kaplowitz HJ, Rabin HR, Stokes D, Light M, Regelmann WE: **Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.** *J Clin Microbiol* 1999, **37**:753–757.
8. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremmer N, Sarles J, Raoult D, Rolain JM: **Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients.** *PLoS One* 2008, **3**:e2908.
9. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapnsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR: **Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.** *Proc Natl Acad Sci U S A* 2007, **104**:20529–20533.
10. Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ: **Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of *Inquilinus limosus* gen. nov., sp. nov.** *J Clin Microbiol* 2002, **40**:2062–2069.
11. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD: **Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling.** *J Clin Microbiol* 2004, **42**:5176–5183.
12. Lambiase A, Raia V, Del PM, Sepe A, Carnovale V, Rossano F: **Microbiology of airway disease in a cohort of patients with cystic fibrosis.** *BMC Infect Dis* 2006, **6**:4.
13. Sharma P, Diene SM, Gimenez G, Rolain J-M: **Genome sequence of *Microbacterium yannicii*, a bacterium isolated from cystic fibrosis patient.** *J Bacteriol* 2012, **194**(17):4785.
14. Karojet S, Kunz S, van Dongen JT: ***Microbacterium yannicii* sp. nov., isolated from *Arabidopsis thaliana* roots.** *Int J Syst Evol Microbiol* 2012, **62**:822–826.
15. Orla-Jensen S: *The Lactic acid bacteria.* Denmark: Host and Son, Copenhagen; 1919:1–118.
16. Park YH, Suzuki K, Yim DG, Lee KC, Kim E, Yoon J, Kim S, Kho YH, Goodfellow M, Komagata K: **Suprageneric classification of peptidoglycan group B actinomycetes by nucleotide sequencing of 5S ribosomal RNA.** *Antonie Van Leeuwenhoek* 1993, **64**:307–313.
17. Stackebrandt E, Rainey FA, Ward-Rainey NL: **Proposal for a new hierarchic classification system, actino bacteria classis nov.** *Int J Syst Bacteriol* 1997, **47**:479–491.
18. Schleifer KH, Kandler O: **Peptidoglycan types of bacterial cell walls and their taxonomic implications.** *Bacteriol Rev* 1972, **36**:407–477.
19. Takeuchi M, Hatano K: **Union of the genera *Microbacterium* Orla-Jensen and *Aureobacterium* Collins et al. in a redefined genus *Microbacterium*.** *Int J Syst Bacteriol* 1998, **48**(Pt 3):739–747.
20. Funke G, Falsen E, Barreau C: **Primary identification of *Microbacterium* spp. encountered in clinical specimens as CDC coryneform group A-4 and A-5 bacteria.** *J Clin Microbiol* 1995, **33**:188–192.
21. Funke G, Haase G, Schnitzler N, Schrage N, Reinert RR: **Endophthalmitis due to *Microbacterium* species: case report and review of microbacterium infections.** *Clin Infect Dis* 1997, **24**:713–716.
22. Funke G, von GA, Weiss N: **Primary identification of *Aureobacterium* spp. isolated from clinical specimens as "*Corynebacterium aquaticum*".** *J Clin Microbiol* 1994, **32**:2686–2691.
23. Morohoshi T, Wang WZ, Someya N, Ikeda T: **Genome sequence of *Microbacterium testaceum* StLB037, an N-acylhomoserine lactone-degrading bacterium isolated from potato leaves.** *J Bacteriol* 2011, **193**:2072–2073.
24. Brown SD, Palumbo AV, Panikov N, Ariyawansa T, Klingeman DM, Johnson CM, Land ML, Utturkar SM, Epstein SS: **Draft genome sequence for *microbacterium laevaniformans* strain OR221: a bacterium tolerant to metals, nitrate, and low pH.** *J Bacteriol* 2012, **194**:3279–3280.
25. Lundquist M, Caspersen MB, Wikstrom P, Forsman M: **Discrimination of *Francisella tularensis* subspecies using surface enhanced laser desorption ionization mass spectrometry and multivariate data analysis.** *FEMS Microbiol Lett* 2005, **243**:303–310.
26. Seng P, Drancourt M, Gourié F, La SB, Fournier PE, Rolain JM, Raoult D: **Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.** *Clin Infect Dis* 2009, **49**:543–551.
27. Diene SM, Merhej V, Henry M, El FA, Roux V, Robert C, Azza S, Gavory F, Barbe V, La SB, Raoult D, Rolain JM: **The rhizome of the multidrug-resistant *Enterobacter aerogenes* genome reveals how new "killer bugs" are created because of a sympatric lifestyle.** *Mol Biol Evol* 2013, **30**:369–383.
28. Adderson EE, Boudreaux JW, Hayden RT: **Infections caused by coryneform bacteria in pediatric oncology patients.** *Pediatr Infect Dis J* 2008, **27**:136–141.
29. Alonso-Echanove J, Shah SS, Valenti AJ, Dirrigl SN, Carson LA, Arduino MJ, Jarvis WR: **Nosocomial outbreak of *Microbacterium* species bacteremia among cancer patients.** *J Infect Dis* 2001, **184**:754–760.

30. Giammanco GM, Pignato S, Grimont PA, Grimont F, Santangelo C, Leonardi G, Giuffrida A, Legname V, Giammanco G: **Interstitial pulmonary inflammation due to *Microbacterium* sp. after heart transplantation.** *J Med Microbiol* 2006, **55**:335–339.
31. Hirji Z, Saragosa R, Dedier H, Crump M, Franke N, Burrows L, Jamieson F, Brown S, Gardam MA: **Contamination of bone marrow products with an actinomycete resembling *Microbacterium* species and reinfusion into autologous stem cell and bone marrow transplant recipients.** *Clin Infect Dis* 2003, **36**:e115–e121.
32. Ko KS, Oh WS, Lee MY, Peck KR, Lee NY, Song JH: **A new *Microbacterium* species isolated from the blood of a patient with fever: *Microbacterium pyrexiae* sp. nov.** *Diagn Microbiol Infect Dis* 2007, **57**:393–397.
33. Laffineur K, Avesani V, Cornu G, Charlier J, Janssens M, Wauters G, Delmee M: **Bacteremia due to a novel *Microbacterium* species in a patient with leukemia and description of *Microbacterium paraoxydans* sp. nov.** *J Clin Microbiol* 2003, **41**:2242–2246.
34. Lau SK, Woo PC, Woo GK, Yuen KY: **Catheter-related *Microbacterium* bacteremia identified by 16S rRNA gene sequencing.** *J Clin Microbiol* 2002, **40**:2681–2685.
35. Gneiding K, Frodl R, Funke G: **Identities of *Microbacterium* spp. encountered in human clinical specimens.** *J Clin Microbiol* 2008, **46**:3646–3652.
36. Mendes R, Pizzirani-Kleiner AA, Araujo WL, Raaijmakers JM: **Diversity of cultivated endophytic bacteria from sugarcane: genetic and biochemical characterization of *Burkholderia cepacia* complex isolates.** *Appl Environ Microbiol* 2007, **73**:7259–7267.
37. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: **MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.** *Mol Biol Evol* 2011, **28**:2731–2739.
38. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O: **The RAST Server: rapid annotations using subsystems technology.** *BMC Genomics* 2008, **9**:75.

doi:10.1186/1471-2180-13-97

Cite this article as: Sharma *et al.*: Phenotypic and genotypic properties of *Microbacterium yannicii*, a recently described multidrug resistant bacterium isolated from a lung transplanted patient with cystic fibrosis in France. *BMC Microbiology* 2013 **13**:97.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

